Deep Braining...
TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

12/05 State of Market Close Report - Stocks edge higher into the close as tech leads and small caps lag; long yields remain above 4%, silver and natural gas rally, Bitcoin slips below $90k Read Report

Type a symbol to have the AI size it up — or skim today’s 🔥 picks and latest headlines.

NVDA AMZN TSLA GME
May your tendies be crispy and your bags be light.
Today’s Picks — AI says these have juice | See All Recent Picks
12/05/2025 Conf 82% Score 0.950

DG Active (—)
Risk Score
48
Pick Date12/05/2025
Horizon7d
Entry127.71-129.50
Exit137.00-140.00
Stop121.50
Expected Gains8.00%
Rationale:

Dollar General just nuked the bears: 31.5% operating profit jump, 43.8% net income rip, and a guidance raise while the stock yeets to fresh 52‑week highs. Price is 127.71 sitting miles above every moving average (10‑day SMA 108.08, 20‑day 104.96, 50‑day 102.94) with a juiced MACD (3.28 vs 1.41 signal) and a fat 1.87 histogram screaming full send. RSI at 82.38? That’s not overbought, that’s over‑owned – everyone who shorted the dollar store recession trade is getting margin‑called. Shorts are still stubborn with 11.64M shares short, 4.02 days‑to‑cover, and an elevated short‑volume ratio north of 56%, but the squeeze_score is 65 and the ratio is rolling over, meaning ammo for a grind‑up as they tap out one by one. You’re buying a guidance‑raised earnings monster at all‑time highs while the crowd still doubts it. Set a stop just under 122, aim for high‑130s in a week, and let Todd Vasos pay for your holiday shopping. Translate to Human Speak

12/05/2025 Conf 80% Score 0.880

WBD Target Hit (—)
Risk Score
58
Pick Date12/05/2025
Horizon1d
Entry24.80-25.20
Exit25.90-26.70
Stop23.90
Expected Gains6.00%
Rationale:

Ticker: WBD Play: Riding the Netflix-buyout hype train like it’s the last chopper out of the content wars. Thesis for degenerates: - The headlines all but scream that Netflix is in exclusive talks to slap an 83B-sized ring on Warner Bros. Discovery. That’s not rumor, that’s full-on corporate situationship. - Stock already went nuclear (+100%+ in a few months) and just printed new 52-week highs, but volume is huge and the news is fresh. This is when momentum junkies show up late and still make money. - Social feeds are lighting up: WBD ripped from obscurity into top-10 mention territory basically overnight. That’s exactly when FOMO money pile-drives the ask. Game plan: - YOLO in around 24.8–25.2 on early dips or tight consolidations. If it blasts straight up and never looks back, you missed it, move on. - Aim to unload the bags between 25.9 and 26.7. That’s about 4–8% from the low end of entry if the squeeze and deal hopium kick in. - Nuke the trade if it cracks 23.9 with volume – that means the party’s over or some nasty headline just dropped. No diamond hands through an M&A rug pull. - Be flat by the close. You’re trading the dopamine of intraday deal mania, not auditioning to be a long-term media analyst. Catalyst receipts: - “Warner Bros. Discovery's Buyer Is All But Certain” (SeekingAlpha) basically flexing that WBD moonshot is about who, not if. Link: https://finnhub.io/api/news?id=e0a6cca553a3921892cc49f701f1957179f32d46ee505cf01e41b1977045dbc3 - “Warner Bros. Discovery and Netflix Enter Exclusive Deal Negotiations” (Yahoo) confirming the big kid table talks are happening. Link: https://finnhub.io/api/news?id=424ace7f4ee3a63b1597688df93e4b937f4fe3d983beaeacbbd6aab12f148496 TL;DR: Buy the target of the Netflix mega-buyout while the herd is still stampeding in, grab your 4–8% scalp, and be gone before lawyers and regulators kill the vibe. Translate to Human Speak

Top Market Movers — biggest % movers right now
Social Trending Stocks — Top Ranked | See All Rankings
SPY
SPDR S&P 500 ETF Trust
0
$685.91 (0.22%)
Rank1
Mentions375
Upvotes1210
NVDA
NVIDIA
1
$182.35 (-0.56%)
Rank2
Mentions259
Upvotes1354
NFLX
Netflix
41
$100.6 (-2.54%)
Rank3
Mentions198
Upvotes1255
WBD
Warner Bros. Discovery
108
$25.91 (5.58%)
Rank4
Mentions134
Upvotes2660
TSLA
Tesla
-1
$454.66 (0.03%)
Rank5
Mentions114
Upvotes441
Top Social Trending — Top Gainers | See All Rankings
API
Agora.io
936
$3.78 (-1.05%)
Current Rank119
Mentions6
Upvotes200
IE
Ivanhoe Electric
881
$14.92 (-2.36%)
Current Rank150
Mentions4
Upvotes29
MYO
Myomo
873
$1.02 (0.06%)
Current Rank256
Mentions2
Upvotes10
AKAN
Akanda
867
$0.89 (-6.07%)
Current Rank149
Mentions4
Upvotes15
VXX
iPath S&P 500 VIX Short-Term Futures
866
$30.68 (-1.32%)
Current Rank148
Mentions4
Upvotes6
Top Social Trending — Top Losers | See All Rankings
JL
J-Long Group
-1153
$5.9 (-7.67%)
Current Rank1153
Mentions1
Upvotes2
INDV
Indivior PLC
-1148
$36.93 (6.73%)
Current Rank1148
Mentions1
Upvotes1
MAMA
Mama's Creations
-1143
$11.47 (-1.8%)
Current Rank1143
Mentions1
Upvotes1
IPA
ImmunoPrecise Antibodies
-1137
Current Rank1137
Mentions1
Upvotes2
CATX
Perspective Therapeutics
-1134
$2.4 (0.42%)
Current Rank1134
Mentions1
Upvotes0
Latest News — headlines that move the tape | See All Articles
The Motley Fool • Dominic Basulto
Should You Buy Bitcoin While It's Under $100,000?

12/05/2025 08:36 PM • Bitcoin is experiencing a price decline but remains attractive compared to other cryptocurrencies. Despite being down 30% from its all-time high, historical patterns suggest potential future recovery and growth.

MSTR STRC STRD STRF STRK AMJB JPM JPMpC JPMpD JPMpJ JPMpK JPMpL JPMpM VYLD
#Bitcoin #cryptocurrency #crypto market #investment #volatility
Read More
GlobeNewswire Inc. • Kirby Mcinerney Llp
Anika Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors ANIK

12/05/2025 08:00 PM • Law firm investigating potential securities fraud at Anika Therapeutics after clinical trial results showed missed endpoints, causing stock price to drop 27.42% on July 30, 2025.

ANIK
#securities fraud #clinical trial #Hyalofast #stock decline
Read More
GlobeNewswire Inc. • Oric Pharmaceuticals
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025

12/05/2025 08:00 PM • ORIC Pharmaceuticals presented promising Phase 1b trial results for enozertinib, demonstrating strong systemic and CNS activity in NSCLC patients with EGFR exon 20 mutations, with high objective response rates and a competitive safety profile.

ORIC
#enozertinib #NSCLC #EGFR #clinical trial #oncology
Read More
GlobeNewswire Inc. • Rosen Law Firm
JHX DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages James Hardie Industries plc Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – JHX

12/05/2025 07:57 PM • Rosen Law Firm is pursuing a securities class action against James Hardie Industries for allegedly misleading investors about the strength of its North America Fiber Cement segment between May 20 and August 18, 2025.

JHX
#securities lawsuit #class action #investor rights #misleading statements
Read More
The Motley Fool • Joe Tenebruso
Why Rubrik Stock Surged Today

12/05/2025 06:36 PM • Cybersecurity company Rubrik reported strong Q3 performance with 48% revenue growth and 34% increase in subscription ARR, driven by AI-powered solutions and improved profitability.

RBRK
#cybersecurity #AI #data protection #cloud #enterprise technology
Read More
GlobeNewswire Inc. • Annabelle Li
Webus International Limited Issues Clarification on Previous Announcement Related to Expedia Group

12/05/2025 06:00 PM • Webus International Limited issued a clarification regarding its previous press release about an Expedia partnership, stating that its engagement was limited to the Travel Agent Affiliate Program. Expedia has terminated Webus' TAAP access as of November 10, 2025.

WETO EXPE
#partnership #termination #travel tech #TAAP #clarification
Read More
GlobeNewswire Inc. • Rosen Law Firm
ATYR DEADLINE MONDAY: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages aTyr Pharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important December 8 Deadline in Securities Class Action - ATYR

12/05/2025 05:57 PM • Rosen Law Firm is pursuing a securities class action against aTyr Pharma for allegedly providing false and misleading statements about the efficacy of their drug Efzofitimod during the period of January 16, 2025 to September 12, 2025.

ATYR
#securities lawsuit #class action #pharmaceutical #investor rights
Read More
GlobeNewswire Inc. • Robbins Llp
Sprouts Farmers Market, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About Leading the SFM Class Action

12/05/2025 05:52 PM • Sprouts Farmers Market faces a class action lawsuit alleging misleading investors about growth potential, with stock price dropping 26.11% after disappointing Q3 results and reduced fiscal year guidance.

SFM
#class action #shareholder lawsuit #stock decline #investor misleading
Read More
GlobeNewswire Inc. • Robbins Llp
OWL Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Blue Owl Capital Inc.

12/05/2025 05:51 PM • A class action lawsuit has been filed against Blue Owl Capital Inc. alleging the company misled investors about its business prospects, liquidity issues, and potential BDC redemption limitations during February to November 2025.

OWL
#class action #shareholder lawsuit #asset management #private credit #BDC redemptions
Read More
GlobeNewswire Inc. • Robbins Llp
BTDR Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Bitdeer Technologies Group

12/05/2025 05:49 PM • A class action lawsuit has been filed against Bitdeer Technologies Group, alleging the company misled investors about its SEAL04 ASIC chip technology development and research progress, resulting in significant financial losses.

BTDR
#class action #lawsuit #Bitcoin mining #ASIC chip #investor disclosure
Read More